6-K 1 a8176m.htm DIRECTOR/PDMR SHAREHOLDING a8176m
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
 
 
For the month of May 2022
 
Commission File Number 001-15170
 
 
GSK plc
(Translation of registrant's name into English)
 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive office)
 
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
 
 
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
 
 
 
 
 
 
GSK plc (the ‘Company')
Transaction notification
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Dr H Barron
 
b)
Position/status
Chief Scientific Officer and President, R&D
 
c)
Initial notification/ amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
 
ISIN: US37733W1053
 
b)
Nature of the transaction
Acquisition of notional ADSs within Dr Barron's GSK Executive Supplemental Savings Plan account.
 
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
$44.7500
1,151.020
 
 
 
 
 
d)
 
 
 
 
 
e) 
Aggregated information
 
 
Aggregated volume Price

 
N/A (single transaction)
Date of the transaction
2022-05-23 
 
f)
Place of the transaction
 
New York Stock Exchange (XNYS)
 
 
 
 
  SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
GSK plc
 
(Registrant)
 
 
Date: May 25, 2022
 
 
 
 
By:/s/ VICTORIA WHYTE
--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GSK plc